OBJECTIVES: In April 2016, the CDF became a temporary reimbursement fund under the remit of NICE with the aim of collecting observational data to inform subsequent technology appraisals. This research aims to evaluate the use of real world evidence (RWE) collected through the CDF in subsequent re-appraisals.

METHODS: NICE Final Appraisal Determinations for Single Technology Appraisals (STAs) of oncology drugs, and subsequent CDF Final Appraisal Determinations and committee papers from 29/07/2016–12/06/2018 were identified and key data extracted.

RESULTS: CONCLUSIONS: BV demonstrates that NICE will accept high quality observational data to help address clinical uncertainty. However, the current experience with the new CDF is limited and it remains unclear how often real world data being collected through the CDF will be included as evidence in drug re-appraisals, particularly where phase III clinical trial data are available to address areas of uncertainty.